Drugs / ABI-M201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03923478 | Jun 2019 → Jan 2021 | ulcerative colitis | Assembly Biosciences | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-06-27 | Assembly Biosciences | Assembly Biosciences Announces First Patient Dosed with ABI-M201 in Phase 1b Clinical Trial for Mildly to Moderately Active Ulcerative Colitis assemblybio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABI-M201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03923478 ↗ |
| Route | Oral | “of Oral ABI-M201” NCT03923478 ↗ |